Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines designed to overcome tumor resistance mechanisms in cancer. The company operates within the oncology and biopharmaceutical industries, with a core emphasis on targeted therapies against fibroblast growth factor receptor (FGFR) alterations. Tyra Biosciences’ approach centers on its proprietary drug design platform, which aims to predict and counteract acquired resistance mutations that limit the durability of existing targeted cancer therapies.
The company’s primary value drivers are its internally developed small-molecule kinase inhibitors, particularly TYRA-300 and TYRA-200, which are being evaluated for cancers driven by FGFR gene alterations. Tyra Biosciences primarily serves oncology patients with genetically defined tumors, positioning itself within the precision oncology segment. Founded in 2018, the company has evolved from a discovery-stage enterprise into a publicly traded clinical-stage organization following its initial public offering in 2021, with a strategic focus on advancing differentiated FGFR inhibitors into clinical development.
Business Operations
Tyra Biosciences operates as a single-segment organization focused on oncology drug discovery and development, generating no commercial product revenue as of the most recent public filings. Its operations are centered on the research, development, and clinical evaluation of targeted therapies, with expenditures primarily related to research and development activities. The company’s lead clinical program, TYRA-300, is an oral, selective FGFR3 inhibitor designed for bladder cancer and other solid tumors with FGFR3 alterations, while TYRA-200 targets FGFR1/2 alterations and is being evaluated in earlier-stage clinical studies.
The company conducts its research and development primarily in the United States, leveraging internal capabilities alongside third-party contract research organizations for clinical trials and manufacturing. Tyra Biosciences controls its proprietary SNÅP (Structure-Based Neoantigenic Prediction) platform, which is used to design compounds intended to address resistance mutations. As of publicly available information, the company does not report material revenue from partnerships and has not disclosed any major joint ventures contributing to operating income.
Strategic Position & Investments
Tyra Biosciences’ strategic direction is focused on advancing its FGFR inhibitor pipeline through clinical proof-of-concept while maintaining ownership of its core intellectual property. Growth initiatives emphasize the clinical expansion of TYRA-300 into additional FGFR3-altered indications and the progression of TYRA-200 into later-stage trials, subject to clinical data. The company’s strategy prioritizes differentiated molecular design over broad pipeline diversification, aiming to compete in areas where existing FGFR therapies show limitations due to resistance or tolerability.
The company has not announced large-scale acquisitions and instead relies on internal research investment to build its pipeline. Capital raised through public equity offerings has been primarily allocated toward clinical development, preclinical research, and operational scaling. Emerging areas of focus include the application of its predictive resistance modeling to additional kinase targets, though public disclosures indicate that FGFR remains the company’s primary therapeutic focus.
Geographic Footprint
Tyra Biosciences is headquartered in the United States, with its principal executive offices located in San Diego, California. The company’s operational footprint is primarily domestic, encompassing research, clinical management, and corporate functions within the U.S. Clinical trials, however, involve investigational sites that may extend beyond U.S. borders, depending on study design and regulatory requirements.
While the company does not maintain a broad international commercial presence, its clinical development activities provide it with indirect exposure to international markets through multinational trial participation. As of the latest public disclosures, Tyra Biosciences does not report significant foreign subsidiaries or standalone international operating entities.
Leadership & Governance
Tyra Biosciences was founded by a team of biotechnology professionals with experience in oncology drug development. The leadership team emphasizes a science-driven culture focused on rational drug design and long-term value creation through clinically differentiated assets. Corporate governance follows standard U.S. public company practices, with oversight provided by a board of directors comprised of industry and financial professionals.
Key executives include:
- Todd Harris – Chief Executive Officer
- Todd Harris – President
- Sanjay S. Shukla, M.D., M.S. – Chief Medical Officer
- Jamie Freedman – Chief Financial Officer
- Mollie Leoni, Ph.D. – Chief Business Officer
Management’s stated strategic vision centers on advancing targeted oncology therapies that address unmet medical needs caused by therapeutic resistance, while maintaining disciplined capital allocation and scientific rigor.